ALLO Nov 2023 5.000 call
| Previous close | 0.1300 |
| Open | 0.1500 |
| Bid | 0.1000 |
| Ask | 0.2500 |
| Strike | 5.00 |
| Expiry date | 2023-11-17 |
| Day's range | 0.1300 - 0.2400 |
| Contract range | N/A |
| Volume | |
| Open interest | 373 |
GlobeNewswireAllogene Therapeutics Announces Participation in September Investor Conference
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in an upcoming investor conference in September. Baird 2023 Global Healthcare ConferenceTuesday, September 12, 202312:45PM PT/3:45PM ET Any available webcasts will be posted to the Company's website at www.allogene.com under the In
GlobeNewswireAllogene Therapeutics Appoints Earl Douglas as General Counsel
Earl Douglas General Counsel, Allogene Therapeutics SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General Counsel. Mr. Douglas will oversee all aspects of the Company’s legal function and serve as a member of the Leadership Team. “We are excited to welcome Earl w
ZacksAllogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss
Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.
